Company Insights

LGND supplier relationships

Explore interactive graphBrowse insights index
LGND supplier relationship map

LGND Supplier Map: Hovione, Novan, Advisors — What investors need to know

Ligand (LGND) operates as a licensing-and-commercialization platform that also controls a proprietary excipient, Captisol, which it procures through third‑party manufacturing and uses to enable partner drug formulations. The company monetizes via royalties and license fees on partnered assets, direct commercialization through subsidiaries, and recurring purchases of Captisol tied to product supply; the Hovione relationship is the central operational supplier linkage that underpins Captisol availability and short‑to‑medium term purchase commitments. For a deeper view of counterparty exposure and supplier risk profiling, visit https://nullexposure.com/.

Why Captisol and Hovione are core to the operating model

Captisol is a specialty cyclodextrin used to improve solubility and stability of Ligand-enabled formulations. Ligand sources Captisol from Hovione, whose facilities in Ireland and Portugal perform primary production—this makes the Hovione relationship both operationally critical and a concentrated supplier risk. According to Ligand’s Form 10‑K for FY2024, Ligand has binding purchase commitments for Captisol totaling $21.6 million as of December 31, 2024, of which $9.0 million is payable within a year, and the underlying supply agreement features automatic renewals into multi‑year terms. That structure produces a blend of near‑term payable obligations and auto‑renewing longer‑term contracting, which investors should treat as a mix of committed spend and durable supplier dependency.

All relationships identified — concise, investor‑focused summaries

  • Hovione — Ligand contracts Hovione to supply Captisol and has purchase commitments under a supply agreement; Ligand disclosed manufacturing and purchase commitments in its FY2024 Form 10‑K.
    Source: Ligand Form 10‑K (FY2024).

  • Hovione FarmaCiencia S.A. — Named as a party to the original Captisol Supply Agreement dated December 20, 2002, indicating the supply network is structured across Hovione affiliates.
    Source: Ligand Form 10‑K (FY2024).

  • Hovione International Limited — Listed among the Hovione entities to the December 20, 2002 Captisol Supply Agreement, evidencing a multi‑jurisdictional contracting footprint.
    Source: Ligand Form 10‑K (FY2024).

  • Hovione LLC — Identified as a contract party in the Captisol Supply Agreement, confirming the US‑entity presence in the supply chain architecture.
    Source: Ligand Form 10‑K (FY2024).

  • Hovione Pharmascience Limited — Also named in the December 20, 2002 supply agreement, reinforcing that multiple Hovione affiliates participate in Captisol manufacturing/distribution.
    Source: Ligand Form 10‑K (FY2024).

  • Acrotech Biopharma LLC — Appears as successor‑in‑interest to Spectrum Pharmaceuticals in an addendum (May 22, 2019) to a license agreement originally dated March 8, 2013, signaling legacy licensing transitions and third‑party license administration.
    Source: Ligand Form 10‑K (FY2024).

  • Latham & Watkins LLP — Serving as lead counsel to Ligand in recent corporate activity, indicating the firm’s role on transaction legal work.
    Source: Yahoo Finance report on Ligand subsidiary activity (Mar 2026).

  • Novan, Inc. — Ligand acquired rights to ZELSUVMI and the NITRICIL platform from Novan in September 2023, providing Ligand with an asset set that it is commercializing through a new subsidiary.
    Source: Yahoo Finance and BioSpace coverage (Mar 2026); transaction disclosed in company announcements.

  • Raymond James & Associates, Inc. — Acting as financial advisor to Ligand and its Pelthos subsidiary in corporate combination activity, reflecting external placement and transaction advisory support.
    Source: Yahoo Finance report (Mar 2026).

  • Stifel, Nicolaus — Named in industry coverage as Ligand’s partner for an at‑the‑market (ATM) facility and capital access, indicating an available equity execution channel.
    Source: Zacks / SCR commentary referencing Stifel (Mar 2026).

  • Agenus — Ligand paid $75 million to Agenus to acquire interests and a royalty stream in oncology programs, demonstrating strategic asset purchases to build the company’s oncology exposure.
    Source: Pharmaphorum reporting on the Agenus transaction (Mar 2026).

What the constraints reveal about LGND’s supplier posture

  • Contracting posture: Ligand’s Captisol supply is governed by agreements that combine short‑term payment obligations ($9.0M payable within a year) with auto‑renewing multi‑year terms (original term extended with two‑year renewal cadence), producing a mix of committed near‑term cash outflow and durable contractual continuity. This is a company‑level signal drawn from Ligand’s FY2024 disclosure.

  • Concentration and criticality: Hovione is Ligand’s named third‑party manufacturer for Captisol and is therefore a single, concentrated supplier for a material operational input; the relationship is functionally critical because Captisol supports downstream partnered product formulations (company‑level signal supported by explicit 10‑K references to Hovione).

  • Spend magnitude and maturity: Reported purchase commitments of $21.6M as of Dec‑31‑2024 place Captisol procurement in a mid‑range spend band and reflect a long‑standing contractual relationship (Captisol agreements date back to 2002 with amendments in 2020 and 2021), indicating both meaningful committed spend and contractual maturity.

  • Operational implication: The combination of committed spend, a sole named manufacturer, and auto‑renewing terms means investors should monitor downstream demand for Captisol, Hovione capacity and geographic risk (Ireland/Portugal), and the tenor of any future supply amendments.

Mid‑analysis: if you want a structured counterparty exposure review or supplier concentration dashboard, visit https://nullexposure.com/ for tools and reports.

Investment implications and risk checklist

  • Upside: Outsourced manufacturing with a multi‑year supply framework supports predictable availability of Captisol for Ligand’s partners and internal commercialization efforts, reducing short‑term production execution risk.
  • Downside concentration: Reliance on Hovione and its affiliates creates single‑point supplier exposure; any interruption in Irish/Portuguese production would immediately affect product supply and potentially royalties.
  • Capital flexibility: The availability of an ATM facility with Stifel and advisory arrangements with Raymond James indicate access to execution channels for capital or strategic transactions.
  • Strategic execution: Recent asset acquisitions and licenses (Novan assets, Agenus interest) are consistent with Ligand’s monetization playbook of acquiring or licensing assets and commercializing through subsidiaries—this increases revenue optionality but also increases working capital and supply needs tied to Captisol.

Final read for investors

Hovione is the single largest supplier relationship investors must model when assessing LGND operational risk, supported by publicly disclosed purchase commitments and long‑standing supply contracts. Ligand’s broader counterparty set—licensees, advisors, and strategic sellers like Novan and Agenus—shapes revenue pathways but does not remove the operational dependency on Captisol sourcing. For active investors and operators building scenario models, prioritize disruption scenarios to Hovione production, monitoring of purchase commitment amortization, and the revenue impact of newly acquired assets.

If you want a tailored supplier risk brief or a counterparty exposure memo for LGND, start here: https://nullexposure.com/.